Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Biopharmaceuticals Manufacturers (US)(?)

Council Members in this Study Group: 36

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Richard Anthony, PhD, Board member, Janus Pharmaceuticals, Inc.Richard Anthony, PhD
Board member
Janus Pharmaceuticals, Inc.

Richard Anthony, PhD, is the Chief Executive Officer at Catalyst Pharma Group, Inc., California, a contract research organization providing clinical development, regulatory and licensing representative services for pharmaceutical and biotechnology companies. He also serves as the Board Member of Janus...

Leo Pavliv, RPh, MBA
VP Operations
Cumberland Pharmaceuticals, Inc.

Leo Pavliv, RPh, MBA, is Vice President Operations at Cumberland Pharmaceuticals in Tennessee. His job responsibilities include directing overall drug development activities for numerous products, regulatory affairs, product development, clinical and non-clinical development, manufacturing, and quality...

Frank Malinoski, MD
Senior Vice President
Medimmune, Inc.

Frank Malinoski MD, PhD, is the President of TD Consultancy and the Senior Vice President of Medical and Scientific Affairs at MedImmune, Inc. in Gaithersburg, Maryland. He has over 20 years of experience in vaccine and immunotherapeutic development. Dr. Malinoski has served as the Executive Vice President...

Peter Culpepper, CPA, MBA, Chief Financial Officer, Provectus Pharmaceuticals, Inc.Peter Culpepper, CPA, MBA
Chief Financial Officer
Provectus Pharmaceuticals, Inc.

Peter Culpepper is the Chief Financial Officer at Provectus Pharmaceuticals. Mr. Culpepper has experience in prescription (therapeutic), biotech, healthcare OTC, specialty pharma, and medical device products. Previous to that, Mr. Culpepper served as the Chief Financial Officer at Felix Culpepper International,...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Sterile Injectables Contract Manufacturing Market Outlook | 02-28-2008
Analysis of: Jubilant News for Hollister-Stier | www.contractpharma.com
Author: GLG Expert Contributor

As demand of the sterile injectables products grows, more and more contract manufacturers are evaluating this landscape as a potential opportunity for growth.  The major concerns in this market outlook are how complex is the technology, how much capacity is needed and will this technology be the...

Sustainable Cost Cutting Efforts Through Strategic Partnerships | 01-25-2008
Analysis of: Pfizer, Novartis, Amgen: cutting costs could boost short-term profits | www.pharmaceutical-business-review.com
Author: GLG Expert Contributor

In today's ever changing pharmaceutical/biotech landscape, manufacturers need to take an aggressive approach to reduce cost while developing their robust pipelines.  To do this successfully, manufacturers need to focus on their core competencies as strategically determined by the senior management...

PDE-5 class effect on Raynauds may provide evidence that SLx-2101 will work | 07-02-2007
Author: Richard Anthony, PhD, Board member, Janus Pharmaceuticals, Inc.

Viagra (sildenafil) a same a PDE-5 same  class compound as SLx-2101 has shown efficacy for Raynaud's by significantly reducing the frequency and duration of Raynaud attacks and improved capillary flow velocity by 400%, according to a study led by Roland Fries, M.D and published online...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Pharmaceuticals Manufacturer
  • Biotechnology Manufacturer
  • Pharmaceuticals/Biotechnology Research Services
  • Consultancy, Pharma-Focused
  • Individual/Small Consultancy

Most Common Job Types:

  • Director
  • President
  • Manufacturing Director
  • Research & Development Manager
  • Research Scientist
  • Chief Medical Officer
  • Chief Financial Officer
  • Owner
  • Operations Executive
  • Quality Control Supervisor
  • Consultant

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-04T17:45:17.897